Improved Insulin Sensitivity: GIP synergizes with GLP-1 to enhance insulin sensitivity in skeletal muscle and liver, reducing insulin resistance and mitigating weight rebound caused by hyperinsulinemia
Real-World Study Findings The study included adults with overweight or obesity without type 2 diabetes who had continuous treatment for one year: Semaglutide (Wegovy) Results: Patients achieved an average weight loss of 14.1% after one year Tirzepatide Results: Patients achieved an average weight loss of 16.5% after one year These real-world results closely mirror the clinical trial findings, demonstrating that the superior weight loss seen with tirzepatide in controlled studies translates to actual patient care settings
[DOI] [PubMed] [Google Scholar] 190.Karry R., Klein E., Ben Shachar D
As a proof of concept, PLGA nanoparticles encapsulated with DDA-GSH-AuNCs were dosed to cultured cells (MCF-7) to evaluate the ability to visualize their uptake using confocal fluorescence microscopy
Data on the function of LAMs in limiting the obesity phenotype have been contradictory, as genetic deletion of Trem2 improved metabolic health in obese mice 29,53,54 , but these effects were not related to the function of Trem2 in immune cells 53
